Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sirion’s Durezol Gets Priority Review, Late June Action Date

This article was originally published in The Pink Sheet Daily

Executive Summary

CEO Butler tells “The Pink Sheet” DAILY Durezol would improve on the current standard of care by offering twice-daily dosing for post-operative ocular inflammation.

You may also be interested in...



Sirion’s Durezol Cleared For Post-Op Ocular Use

The first-in-class topical steroid is set to launch in the fourth quarter.

Sirion’s Durezol Cleared For Post-Op Ocular Use

The first-in-class topical steroid is set to launch in the fourth quarter.

FDA Panel Supports Sirion’s Durezol, But Dosing May Not Provide Market Niche

Twice-daily dosing would provide a convenience advantage for Durezol over other corticosteroids.

Related Content

Topics

UsernamePublicRestriction

Register

PS067318

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel